Get the Stockscreener App
6.99
0.99%
-0.07
After Hours:
6.94
-0.05
-0.72%
Kamada Ltd stock is traded at $6.99, with a volume of 37,860.
It is down -0.99% in the last 24 hours and down -3.72% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$7.06
Open:
$7
24h Volume:
37,860
Relative Volume:
0.85
Market Cap:
$403.28M
Revenue:
$181.68M
Net Income/Loss:
$20.37M
P/E Ratio:
20.00
EPS:
0.3495
Net Cash Flow:
$17.31M
1W Performance:
-1.41%
1M Performance:
-3.72%
6M Performance:
-21.20%
1Y Performance:
-9.46%
1-Day Range:
$6.93
$7.09
1-Week Range:
$6.9235
$7.31
52-Week Range:
$6.50
$9.35
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
6.99 | 407.32M | 181.68M | 20.37M | 17.31M | 0.3495 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | The Benchmark Company | Buy |
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Kamada Ltd (KMDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kamada Ltd (KMDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kamada Ltd (KMDA) Cash Flow - TradingKey
Kamada Ltd. Revenue Breakdown – NASDAQ:KMDA - TradingView
Kamada Ltd. (KMDA) Stock Analysis: Exploring an 86.78% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Kamada Ltd (KMDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kamada Ltd. (KMDA) Sees Slight Decline as Shares Test Key Support ZoneCall Dominated - dars.gov.et
Kamada stock trades steadily as plasma-derived therapies support revenue growth - Ad-hoc-news.de
Kamada stock holds at Buy as Benchmark cites $50M plasma deal - Investing.com UK
Kamada secures $50M plasma supply deal over three years By Investing.com - Investing.com Nigeria
Kamada Signs $50 Million Plasma Supply Agreement With Biopharmaceutical Firm - Moomoo
Kamada jumps on $50m source plasma dealGlobes - Globes - Israel Business News
Kamada (KMDA) Secures $50M Plasma Supply Agreement - GuruFocus
Kamada Signs Three-Year, $50 Million Plasma Supply Deal to Bolster Growth - TipRanks
Kamada secures $50M plasma supply deal over three years - Investing.com
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies - The Manila Times
Kamada Ltd. (NASDAQ: KMDA) signs three-year $50M plasma supply agreement - Stock Titan
Kamada’s centers plan ~50,000 liters of plasma each at full capacity - Stock Titan
Kamada signs three-year USD 50 million plasma supply agreement with biopharmaceutical company - Bitget
Uri Botzer Net Worth (2026) - GuruFocus
Kamada Showcases New CYTOGAM Data from 2026 ISHLT Meeting, Signaling Potential Uptick in Transplant Use - TipRanks
Kamada highlights study results on CYTOGAM in transplants - Investing.com UK
symbol__ Stock Quote Price and Forecast - CNN
Kamada highlights Cytogam study results - TipRanks
Kamada highlights study results on CYTOGAM in transplants By Investing.com - Investing.com South Africa
Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference - GuruFocus
[6-K] KAMADA LTD Current Report (Foreign Issuer) | KMDA SEC FilingForm 6-K - Stock Titan
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting - GlobeNewswire
How (KMDA) Movements Inform Risk Allocation Models - Stock Traders Daily
Enterprise value to EBITDA forward of Kamada Ltd. – NASDAQ:KMDA - TradingView
Price to earnings forward of Kamada Ltd. – NASDAQ:KMDA - TradingView
Price to earnings forward of Kamada Ltd – TASE:KMDA - TradingView
Enterprise value to EBIT forward of Kamada Ltd. – NASDAQ:KMDA - TradingView
Kamada Ltd outlines plasma-derived therapies strategy. Investor focus on specialty biologics pipelin - Ad-hoc-news.de
Kamada Ltd. Q1 2026 Earnings: EPS Misses Estimates, Stock Declines SlightlyPost-Earnings Reaction - dars.gov.et
Kamada Ltd. (KMDA) Holds Steady Near Support as Technical Indicators Suggest ConsolidationPairs Trade - dars.gov.et
Kamada Ltd. (KMDA) Holds Steady as Shares Trade Near Midpoint of RangeMax Pain Level - dars.gov.et
Trading Systems Reacting to (KMDA) Volatility - Stock Traders Daily
KMDAKamada Ltd Latest SEC Filings - Finviz
Kamada Ltd updates drug portfolio as Nasdaq-listed biopharma pursues growth - ad-hoc-news.de
Kamada (KMDA) Corporate Presentation Summary - Quartr
Daichi Kamada Contract Boost Gives Crystal Palace Sage Win - Read Crystal Palace
KMDA Q1 2026 Earnings: EPS Misses Estimates, Stock Gains SlightlyFull Year Guidance - dars.gov.et
Kamada Ltd Actuals & Estimates (NASDAQ:KMDA) - TradingView
Kamada eyed by Milan and Fiorentina as Crystal Palace midfielder linked with Serie A return - Football Italia
KMDA Forecast — Price Target — Prediction for 2027 - TradingView
Kamada Ltd. (KMDA) Posts Modest Gain as Shares Hold Above Key Support LevelOverbought Signal Alerts - dars.gov.et
KMDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Kamada Ltd (KMDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Daichi Kamada World Cup form gives Crystal Palace fresh momentum - Read Crystal Palace
Japan coach Moriyasu praises Kamada after standout performance in new role - CNA
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):